Objective:Tamoxifen is used as a complementary treatment for estrogen receptor(ER)-positive breast cancer(BCa),but many patients developed resistance.The aim of this study was to examine the role of syndecan-binding p...Objective:Tamoxifen is used as a complementary treatment for estrogen receptor(ER)-positive breast cancer(BCa),but many patients developed resistance.The aim of this study was to examine the role of syndecan-binding protein(SDCBP)silencing in ER-positive BCa cells.Methods:In MCF-7/T47D cells,the effects of SDCBP silence/overexpression on cell proliferation and estrogenic response were examined.Cell proliferation was examined using the MTT assay and cell cycle regulators were examined by Western blot.Estrogen response was examined from a luciferase activity and evaluation of transcript levels of p S2 and progesterone receptor(PR)upon estrogen administration.Samples of ER-positive BCa were stained with ERα,PR,and SDCBP antibodies,and their expression correlations were analyzed.Results:We found that SDCBP silencing inhibited the proliferation of ER-positive BCa cells and arrested a greater number of cells in the G1 phase of the cell cycle compared to tamoxifen alone,while SDCBP overexpression limited the anti-cancer effects of tamoxifen.SDCBP silencing and overexpression also enhanced and attenuated the estrogenic response,respectively.Expression of SDCBP was negatively correlated with PR,ERα,and the PR/ERαratio in ER-positive BCa tissue samples.Conclusions:SDCBP may be involved in tamoxifen resistance in ER-positive BCa.Tamoxifen treatment combined with SDCBP silencing may provide a novel treatment for endocrine therapy-resistant BCa.展开更多
Objective: We studied the alterations in the expression of estrogen receptor alpha (ER) in the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinomas (IDC). Methods: The mastectomy specimens of...Objective: We studied the alterations in the expression of estrogen receptor alpha (ER) in the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinomas (IDC). Methods: The mastectomy specimens of 120 cases containing both DCIS and IDC were examined. The expression of ER proteins were examined by immunohistochemistry. The difference of the expression of ER proteins between DCIS and IDC were compared. Results: There were 58.33% of the cases with DCIS expressing ER proteins, and 40.00% of the cases IDC expressing ER proteins. There was a significant decrease of ER expression in IDC compared to DCIS (χ2 = 4.034, P = 0.045). Conclusion: These findings substantiate the notion that breast cancer progression is often associated with alterations in expressions of ER. The underlying mechanisms of these alterations need further investigation.展开更多
基金supported by National Natural Science Foundation of China (Grant No. 81302292 to Xiaolong Qian, Grant No. 81702629 to Jun Zhang, Grant No. 81672636 and 81272358 to Feng Gu, Grant No. 81672637 to Li Fu)
文摘Objective:Tamoxifen is used as a complementary treatment for estrogen receptor(ER)-positive breast cancer(BCa),but many patients developed resistance.The aim of this study was to examine the role of syndecan-binding protein(SDCBP)silencing in ER-positive BCa cells.Methods:In MCF-7/T47D cells,the effects of SDCBP silence/overexpression on cell proliferation and estrogenic response were examined.Cell proliferation was examined using the MTT assay and cell cycle regulators were examined by Western blot.Estrogen response was examined from a luciferase activity and evaluation of transcript levels of p S2 and progesterone receptor(PR)upon estrogen administration.Samples of ER-positive BCa were stained with ERα,PR,and SDCBP antibodies,and their expression correlations were analyzed.Results:We found that SDCBP silencing inhibited the proliferation of ER-positive BCa cells and arrested a greater number of cells in the G1 phase of the cell cycle compared to tamoxifen alone,while SDCBP overexpression limited the anti-cancer effects of tamoxifen.SDCBP silencing and overexpression also enhanced and attenuated the estrogenic response,respectively.Expression of SDCBP was negatively correlated with PR,ERα,and the PR/ERαratio in ER-positive BCa tissue samples.Conclusions:SDCBP may be involved in tamoxifen resistance in ER-positive BCa.Tamoxifen treatment combined with SDCBP silencing may provide a novel treatment for endocrine therapy-resistant BCa.
基金Supported by a grant from the National Science Foundation of China (No. 30772100)
文摘Objective: We studied the alterations in the expression of estrogen receptor alpha (ER) in the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinomas (IDC). Methods: The mastectomy specimens of 120 cases containing both DCIS and IDC were examined. The expression of ER proteins were examined by immunohistochemistry. The difference of the expression of ER proteins between DCIS and IDC were compared. Results: There were 58.33% of the cases with DCIS expressing ER proteins, and 40.00% of the cases IDC expressing ER proteins. There was a significant decrease of ER expression in IDC compared to DCIS (χ2 = 4.034, P = 0.045). Conclusion: These findings substantiate the notion that breast cancer progression is often associated with alterations in expressions of ER. The underlying mechanisms of these alterations need further investigation.
